[HTML][HTML] Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing

IF Orlando, JM Shine, TW Robbins, JB Rowe… - Neuroscience & …, 2023 - Elsevier
Noradrenergic and cholinergic systems are among the most vulnerable brain systems in
neuropsychiatric diseases of ageing, including Alzheimer's disease, Parkinson's disease …

Distinguishing apathy from depression: A review differentiating the behavioral, neuroanatomic, and treatment‐related aspects of apathy from depression in …

KL Lanctôt, Z Ismail, KK Bawa… - … journal of geriatric …, 2023 - Wiley Online Library
Objectives This narrative review describes the clinical features of apathy and depression in
individuals with neurocognitive disorders (NCDs), with the goal of differentiating the two …

Research criteria for the behavioral variant of Alzheimer disease: a systematic review and meta-analysis

R Ossenkoppele, EH Singleton, C Groot… - JAMA …, 2022 - jamanetwork.com
Importance The behavioral variant of Alzheimer disease (bvAD) is characterized by early
and predominant behavioral deficits caused by AD pathology. This AD phenotype is …

Neuropsychiatric symptoms in the dementias

F Assal, JL Cummings - Current opinion in neurology, 2002 - journals.lww.com
Future research directions include both clinical and basic neuroscience investigations. The
detection of early neuropsychiatric symptoms might be a marker for dementia, and the …

[HTML][HTML] Amphetamines improve the motivation to invest effort in Attention-Deficit/Hyperactivity Disorder

TTJ Chong, E Fortunato, MA Bellgrove - Journal of Neuroscience, 2023 - Soc Neuroscience
Prevailing frameworks propose that a key feature of attention-deficit/hyperactivity disorder
(ADHD) is lower motivation. An important component of motivation is the willingness to …

Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis

MCB David, M Del Giovane, KY Liu… - Journal of Neurology …, 2022 - jnnp.bmj.com
Background Dysfunction of the locus coeruleus-noradrenergic system occurs early in
Alzheimer's disease, contributing to cognitive and neuropsychiatric symptoms in some …

[HTML][HTML] Noradrenergic neuromodulation in ageing and disease

F Krohn, E Lancini, M Ludwig, M Leiman… - Neuroscience & …, 2023 - Elsevier
The locus coeruleus (LC) is a small brainstem structure located in the lower pons and is the
main source of noradrenaline (NA) in the brain. Via its phasic and tonic firing, it modulates …

Challenges in anti‐aging medicine–trends in biomarker discovery and therapeutic interventions for a healthy lifespan

I Popescu, J Deelen, M Illario… - Journal of Cellular and …, 2023 - Wiley Online Library
We are facing a growing aging population, along with increasing pressure on health
systems, caused by the impact of chronic co‐morbidities (ie cancer, cardiovascular and …

The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease

P Krashia, E Spoleti, M D'Amelio - Frontiers in Psychiatry, 2022 - frontiersin.org
Neuropsychiatric symptoms (NPS) occur in nearly all patients with Alzheimer's Disease
(AD). Most frequently they appear since the mild cognitive impairment (MCI) stage preceding …

Apathy and motivation: biological basis and drug treatment

H Costello, M Husain, JP Roiser - Annual Review of …, 2024 - annualreviews.org
Apathy is a disabling syndrome associated with poor functional outcomes that is common
across a broad range of neurological and psychiatric conditions. Currently, there are no …